Publications

Journal Article
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Ppublish 1516 citations
Electronic publication date
December 16, 2006

View on Pubmed.gov 17063185 | View on doi.org 10.1038/nri1961

Interferons, immunity and cancer immunoediting.

Search for publications in this journal Nat Rev Immunol - 6(11):836-48

Abstract

A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.

References

No references provided.

Cited by 1516 citations (total)

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1.

Electronic publication date January 14, 2009

Search for publications in this journal PLoS One

Shuo Wang [...] Antonis E Koromilas et al.

Inactivation of p27 Kip1 is implicated in tumorigenesis and has both prognostic and treatment-predictive values for many types of human...

Journal Article Research Support, Non-U.S. Gov't Review

The anticancer immune response: indispensable for therapeutic success?

Electronic publication date July 11, 2008

Search for publications in this journal J Clin Invest

Laurence Zitvogel [...] Guido Kroemer et al.

Although the impact of tumor immunology on the clinical management of most cancers is still negligible, there is increasing evidence...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances